WO2004012574A3 - Negative selections assays, and compositions thereof - Google Patents

Negative selections assays, and compositions thereof Download PDF

Info

Publication number
WO2004012574A3
WO2004012574A3 PCT/US2003/022241 US0322241W WO2004012574A3 WO 2004012574 A3 WO2004012574 A3 WO 2004012574A3 US 0322241 W US0322241 W US 0322241W WO 2004012574 A3 WO2004012574 A3 WO 2004012574A3
Authority
WO
WIPO (PCT)
Prior art keywords
assays
compositions
negative selections
cytotoxicity
selections
Prior art date
Application number
PCT/US2003/022241
Other languages
French (fr)
Other versions
WO2004012574A2 (en
Inventor
Carl Alexander Kamb
Original Assignee
Deltagen Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deltagen Proteomics Inc filed Critical Deltagen Proteomics Inc
Priority to AU2003256572A priority Critical patent/AU2003256572A1/en
Publication of WO2004012574A2 publication Critical patent/WO2004012574A2/en
Publication of WO2004012574A3 publication Critical patent/WO2004012574A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to methods for performing negative selection assays leading to the identification of cytostatic or cytotoxic agents that cause a lethal phenotype. The invention is useful also for evaluation of conditional cytotoxicity and cell-specific cytotoxicity.
PCT/US2003/022241 2002-07-16 2003-07-16 Negative selections assays, and compositions thereof WO2004012574A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003256572A AU2003256572A1 (en) 2002-07-16 2003-07-16 Negative selections assays, and compositions thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39617102P 2002-07-16 2002-07-16
US60/396,171 2002-07-16

Publications (2)

Publication Number Publication Date
WO2004012574A2 WO2004012574A2 (en) 2004-02-12
WO2004012574A3 true WO2004012574A3 (en) 2005-02-03

Family

ID=31495712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022241 WO2004012574A2 (en) 2002-07-16 2003-07-16 Negative selections assays, and compositions thereof

Country Status (2)

Country Link
AU (1) AU2003256572A1 (en)
WO (1) WO2004012574A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2553097A1 (en) 2010-03-26 2013-02-06 Integratech Proteomics, LLC Controlled release hybrid systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADRA ET AL.: "RhoGDIgama : A GDP-dissociation inhibitor for Rho proteins with preferentionl expression in brain and pancreas", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 9, 29 April 1997 (1997-04-29), USA, pages 4279 - 4284, XP002903187 *
DATABASE GENBANK [online] 17 April 2001 (2001-04-17), WAN ET AL., XP002903186, accession no. NCBI Database accession no. (AF250306) *

Also Published As

Publication number Publication date
AU2003256572A8 (en) 2004-02-23
WO2004012574A2 (en) 2004-02-12
AU2003256572A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2005005679A3 (en) Super-hydrophobic surfaces, methods of their construction and uses therefor
ZA200305993B (en) Herbicidal compositions.
EP1691842A4 (en) Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
WO2005047898A3 (en) Methods and compositions for identifying therapeutic compounds
AU3652102A (en) Compounds and their uses
TW200511992A (en) Sulfonamide substituted imidazoquinolines
WO2003070701A3 (en) Syntheses of quinazolinones
WO2006088803A3 (en) Polypeptides from staphylococcus aureus and methods of use
MA29154B1 (en) GEMCITABINE AMIDE PROMEDICAMENT, COMPOSITIONS AND USES THEREOF
WO2004014893A3 (en) Antimicrobial aza-bicyclic derivates, their compositions and uses
PL1613598T3 (en) Methods of preparing aripiprazole crystalline forms
AP2005003195A0 (en) Herbicidal compositions.
WO2005075467A3 (en) Crystalline forms of zolmitriptan
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
HK1049796B (en) Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
AU8738401A (en) Novel kallikrein gene
EP1915369A4 (en) Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors
ZA200604874B (en) Pharmaceutical compositions
WO2007022321A3 (en) Substituted indoles and use thereof
WO2002064574A3 (en) Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
ZA200501387B (en) Antimicrobial compositions.
WO2001061346A3 (en) Methods for identifying agents causing a lethal phenotype
WO2006027345A3 (en) Novel 3-thia-10-aza-phenanthrene derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 08.06.2005)

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP